Browsing ICR Divisions by author "Kaiser, Martin"
Now showing items 41-60 of 86
-
Implementation of Whole-Body MRI (MY-RADS) within the OPTIMUM/MUKnine multi-centre clinical trial for patients with myeloma.
Rata, M; Blackledge, M; Scurr, E; Winfield, J; Koh, D-M; et al. (SPRINGER, 2022-07-28)BACKGROUND: Whole-body (WB) MRI, which includes diffusion-weighted imaging (DWI) and T1-w Dixon, permits sensitive detection of marrow disease in addition to qualitative and quantitative measurements of disease and response ... -
Inter-observer agreement of baseline whole body MRI in multiple myeloma.
Croft, J; Riddell, A; Koh, D-M; Downey, K; Blackledge, M; et al. (BMC, 2020-07-14)BACKGROUND: Whole body magnetic resonance imaging (MRI) is now incorporated into international guidance for imaging patients with multiple myeloma. The aim of this study was to investigate inter-observer agreement of triple ... -
Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study.
Guo, C; Chénard-Poirier, M; Roda, D; de Miguel, M; Harris, SJ; et al. (ELSEVIER SCIENCE INC, 2020-11-01)BACKGROUND: CH5126766 (also known as VS-6766, and previously named RO5126766), a novel MEK-pan-RAF inhibitor, has shown antitumour activity across various solid tumours; however, its initial development was limited by ... -
Interobserver agreement of whole-body magnetic resonance imaging is superior to whole-body computed tomography for assessing disease burden in patients with multiple myeloma.
Lai, AYT; Riddell, A; Barwick, T; Boyd, K; Rockall, A; et al. (SPRINGER, 2020-01-01)OBJECTIVES: Whole-body MRI (WB-MRI) is recommended by the International Myeloma Working Group for all patients with asymptomatic myeloma and solitary plasmacytoma and by the UK NICE guidance for all patients with suspected ... -
Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results.
Auner, HW; Brown, SR; Walker, K; Kendall, J; Dawkins, B; et al. (SPRINGERNATURE, 2022-04-01)The all-oral combination of ixazomib, cyclophosphamide, and dexamethasone (ICD) is well tolerated and effective in newly diagnosed and relapsed multiple myeloma (MM). We carried out MUKeight, a randomised, controlled, open, ... -
Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial.
Jackson, GH; Davies, FE; Pawlyn, C; Cairns, DA; Striha, A; et al. (FERRATA STORTI FOUNDATION, 2021-07-01)The optimal way to use immunomodulatory drugs as components of induction and maintenance therapy for multiple myeloma is unresolved. We addressed this question in a large phase III randomized trial, Myeloma XI. Patients ... -
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
Jackson, GH; Davies, FE; Pawlyn, C; Cairns, DA; Striha, A; et al. (ELSEVIER SCIENCE INC, 2019-01-01)BACKGROUND: Patients with multiple myeloma treated with lenalidomide maintenance therapy have improved progression-free survival, primarily following autologous stem-cell transplantation. A beneficial effect of lenalidomide ... -
Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life.
Terpos, E; Mikhael, J; Hajek, R; Chari, A; Zweegman, S; et al. (SPRINGERNATURE, 2021-02-18)Treatment options in multiple myeloma (MM) are increasing with the introduction of complex multi-novel-agent-based regimens investigated in randomized clinical trials. However, application in the real-world setting, including ... -
Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk.
de Tute, RM; Pawlyn, C; Cairns, DA; Davies, FE; Menzies, T; et al. (LIPPINCOTT WILLIAMS & WILKINS, 2022-09-01)PURPOSE: Minimal residual disease (MRD) can predict outcomes in patients with multiple myeloma, but limited data are available on the prognostic impact of MRD when assessed at serial time points in the context of maintenance ... -
MUKnine OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia.
Brown, S; Sherratt, D; Hinsley, S; Flanagan, L; Roberts, S; et al. (BMJ PUBLISHING GROUP, 2021-03-24)INTRODUCTION: Multiple myeloma (MM) is a plasma cell tumour with over 5800 new cases each year in the UK. The introduction of biological therapies has improved outcomes for the majority of patients with MM, but in approximately ... -
MUKtwelve protocol: a phase II randomised, controlled, open, parallel group, multicentre trial of selinexor, cyclophosphamide and prednisolone (SCP) versus cyclophosphamide and prednisolone (CP) in patients with relapsed or refractory multiple myeloma.
Kendall, J; Hall, A; Roberts, S; Brown, S; Boyd, K; et al. (BMJ PUBLISHING GROUP, 2022-10-26)INTRODUCTION: Multiple myeloma is a malignancy of plasma cells with around 6000 new cases per year in the UK. Cyclophosphamide plus prednisolone is considered a standard of care for disease and symptom control in the ... -
Multiple myeloma risk variant at 7p15.3 creates an IRF4-binding site and interferes with CDCA7L expression.
Li, N; Johnson, DC; Weinhold, N; Studd, JB; Orlando, G; et al. (NATURE PUBLISHING GROUP, 2016-11-24)Genome-wide association studies have identified several risk loci for multiple myeloma (MM); however, the mechanisms by which they influence MM are unknown. Here by using genetic association data and functional characterization, ... -
Mutational processes contributing to the development of multiple myeloma.
Hoang, PH; Cornish, AJ; Dobbins, SE; Kaiser, M; Houlston, RS (NATURE PUBLISHING GROUP, 2019-08-06)To gain insight into multiple myeloma (MM) tumorigenesis, we analyzed the mutational signatures in 874 whole-exome and 850 whole-genome data from the CoMMpass Study. We identified that coding and non-coding regions are ... -
Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugs.
Jones, JR; Barber, A; Le Bihan, Y-V; Weinhold, N; Ashby, C; et al. (SPRINGERNATURE, 2021-10-01) -
Neutral tumor evolution in myeloma is associated with poor prognosis.
Johnson, DC; Lenive, O; Mitchell, J; Jackson, G; Owen, R; et al. (AMER SOC HEMATOLOGY, 2017-10-05)Recent studies suggest that the evolutionary history of a cancer is important in forecasting clinical outlook. To gain insight into the clonal dynamics of multiple myeloma (MM) and its possible influence on patient outcomes, ... -
Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial.
Jackson, GH; Pawlyn, C; Cairns, DA; Striha, A; Collett, C; et al. (WILEY, 2021-03-01)Second-generation immunomodulatory agents, such as lenalidomide, have a more favourable side-effect profile than the first-generation thalidomide, but their optimum combination and duration for patients with newly diagnosed ... -
Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial.
Panopoulou, A; Cairns, DA; Holroyd, A; Nichols, I; Cray, N; et al. (AMER SOC HEMATOLOGY, 2023-04-06)Prediction of individual patient benefit from lenalidomide (Len) maintenance after autologous stem cell transplant (ASCT) remains challenging. Here, we investigated extended molecular profiling for outcome prediction in ... -
Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control.
Pawlyn, C; Bright, MD; Buros, AF; Stein, CK; Walters, Z; et al. (SPRINGERNATURE, 2017-03-31)Myeloma is heterogeneous at the molecular level with subgroups of patients characterised by features of epigenetic dysregulation. Outcomes for myeloma patients have improved over the past few decades except for molecularly ... -
Perspectives on the Risk-Stratified Treatment of Multiple Myeloma.
Davies, FE; Pawlyn, C; Usmani, SZ; San-Miguel, JF; Einsele, H; et al. (AMER ASSOC CANCER RESEARCH, 2022-07-06)The multiple myeloma treatment landscape has changed dramatically. This change, paralleled by an increase in scientific knowledge, has resulted in significant improvement in survival. However, heterogeneity remains in ... -
Phenome-wide Mendelian randomisation analysis of 378,142 cases reveals risk factors for eight common cancers.
Went, M; Sud, A; Mills, C; Hyde, A; Culliford, R; et al. (Springer Science and Business Media LLC, 2024-03-25)For many cancers there are only a few well-established risk factors. Here, we use summary data from genome-wide association studies (GWAS) in a Mendelian randomisation (MR) phenome-wide association study (PheWAS) to identify ...